{"meta":{"totalResults":29,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"yttrium Y 90 monoclonal antibody CC49"}],"definition":{"html":"A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with Yttrium 90 (Y-90). MoAb CC49 recognizes the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Y-90 MoAb CC49 delivers beta particles emitting Y-90 radionuclide directly to tumor cells that express TAG-72, thereby this agent may be used in radioimmunotherapeutic treatment of cancers.","text":"A radioimmunoconjugate of the humanized monoclonal antibody (MoAb) CC49 labeled with Yttrium 90 (Y-90). MoAb CC49 recognizes the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Y-90 MoAb CC49 delivers beta particles emitting Y-90 radionuclide directly to tumor cells that express TAG-72, thereby this agent may be used in radioimmunotherapeutic treatment of cancers."},"drugInfoSummaryLink":null,"nciConceptId":"C2597","nciConceptName":"Y 90 Monoclonal Antibody CC49","termId":38082,"name":"Y 90 monoclonal antibody CC49","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"y-90-monoclonal-antibody-cc49"},{"aliases":[{"type":"Synonym","name":"MOAB M195, yttrium Y 90"},{"type":"Synonym","name":"monoclonal antibody M195, yttrium Y 90"},{"type":"Abbreviation","name":"Y 90 MoAb M195"},{"type":"Synonym","name":"yttrium Y 90 monoclonal antibody M195"}],"definition":{"html":"A radioimmunoconjugate of humanized M195 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb M195 is reactive with the cell surface antigen CD33, a glycoprotein found on myeloid leukemia blasts and early hematopoietic progenitor cells but not on normal stem cells. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both imaging and therapeutic uses.","text":"A radioimmunoconjugate of humanized M195 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb M195 is reactive with the cell surface antigen CD33, a glycoprotein found on myeloid leukemia blasts and early hematopoietic progenitor cells but not on normal stem cells. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both imaging and therapeutic uses."},"drugInfoSummaryLink":null,"nciConceptId":"C2248","nciConceptName":"Y 90 Monoclonal Antibody M195","termId":38025,"name":"Y 90 monoclonal antibody M195","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"y-90-monoclonal-antibody-m195"},{"aliases":null,"definition":{"html":"A radioimmunoconjugate consisting of the murine IgG1 anti-CD19 monoclonal antibody (MoAb) BU12 labeled with the beta-emitting radioisotope yttrium Y 90 with radioisotopic and antibody activities.  Yttrium Y 90 anti-CD19 monoclonal antibody BU12 binds to the CD19 molecule, specifically delivering cytotoxic beta radiation to CD19-expressing B cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages. ","text":"A radioimmunoconjugate consisting of the murine IgG1 anti-CD19 monoclonal antibody (MoAb) BU12 labeled with the beta-emitting radioisotope yttrium Y 90 with radioisotopic and antibody activities.  Yttrium Y 90 anti-CD19 monoclonal antibody BU12 binds to the CD19 molecule, specifically delivering cytotoxic beta radiation to CD19-expressing B cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages. "},"drugInfoSummaryLink":null,"nciConceptId":"C74092","nciConceptName":"Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12","termId":592567,"name":"yttrium Y 90 anti-CD19 monoclonal antibody BU12","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-anti-cd19-monoclonal-antibody-bu12"},{"aliases":[{"type":"Abbreviation","name":"Y 90 AHN-12"}],"definition":{"html":"A radioimmunoconjugate comprised of the monoclonal antibody AHN-12 conjugated to the radioisotope yttrium 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 monoclonal antibody AHN-12 binds to the tyrosine phosphatase CD45, expressed on the surface of normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation.\n","text":"A radioimmunoconjugate comprised of the monoclonal antibody AHN-12 conjugated to the radioisotope yttrium 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 monoclonal antibody AHN-12 binds to the tyrosine phosphatase CD45, expressed on the surface of normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C74093","nciConceptName":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12","termId":587979,"name":"yttrium Y 90 anti-CD45 monoclonal antibody AHN-12","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-anti-cd45-monoclonal-antibody-ahn-12"},{"aliases":[{"type":"Abbreviation","name":"90Y anti-CD45 MAb BC8"},{"type":"Abbreviation","name":"90Y anti-CD45 MoAb BC8"}],"definition":{"html":"A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MoAb) BC8 labeled with yttrium 90 (Y90), with potential immunotherapeutic activity. Yttrium Y 90 anti-CD45 monoclonal antibody BC8 binds to CD45 antigen, a receptor protein-tyrosine phosphatase expressed on the surface of both normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation.","text":"A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MoAb) BC8 labeled with yttrium 90 (Y90), with potential immunotherapeutic activity. Yttrium Y 90 anti-CD45 monoclonal antibody BC8 binds to CD45 antigen, a receptor protein-tyrosine phosphatase expressed on the surface of both normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of beta radiation."},"drugInfoSummaryLink":null,"nciConceptId":"C95698","nciConceptName":"Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8","termId":688830,"name":"yttrium Y 90 anti-CD45 monoclonal antibody BC8","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-anti-cd45-monoclonal-antibody-bc8"},{"aliases":null,"definition":{"html":"A radioimmunoconjugate consisting of the  murine IgG1 monoclonal antibody BW250/183 labeled with yttrium Y 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183 binds to a 95 kD nonspecific cross-reacting antigen (CD66b or NCA-95) on granulocytes,  selectively delivering a cytotoxic dose of Y 90 beta radiation to CD66b-expressing cells. CD66b, a member of the carcinoembryonic antigen (CEA) family with an unknown function, appears early in the differentiation of granulopoietic cells and is expressed on the cell surface of almost all human granulocytes and their more mature precursors.","text":"A radioimmunoconjugate consisting of the  murine IgG1 monoclonal antibody BW250/183 labeled with yttrium Y 90 with potential radioimmunotherapeutic activity. Yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183 binds to a 95 kD nonspecific cross-reacting antigen (CD66b or NCA-95) on granulocytes,  selectively delivering a cytotoxic dose of Y 90 beta radiation to CD66b-expressing cells. CD66b, a member of the carcinoembryonic antigen (CEA) family with an unknown function, appears early in the differentiation of granulopoietic cells and is expressed on the cell surface of almost all human granulocytes and their more mature precursors."},"drugInfoSummaryLink":null,"nciConceptId":"C74094","nciConceptName":"Yttrium Y 90 Anti-CD66 Monoclonal Antibody BW 250/183","termId":589964,"name":"yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-anti-cd66-monoclonal-antibody-bw-250-183"},{"aliases":[{"type":"Abbreviation","name":"FF-21101(90Y)"}],"definition":{"html":"A radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90, with potential antineoplastic activities. Upon administration, the antibody moiety of yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101 binds to CDH3 expressed on tumor cells, thereby specifically delivering cytotoxic beta radiation to CDH3-expressing tumor cells. CDH3, also known as P-cadherin, is a tumor-associated antigen (TAA) and member of the cadherin family; it is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.","text":"A radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90, with potential antineoplastic activities. Upon administration, the antibody moiety of yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101 binds to CDH3 expressed on tumor cells, thereby specifically delivering cytotoxic beta radiation to CDH3-expressing tumor cells. CDH3, also known as P-cadherin, is a tumor-associated antigen (TAA) and member of the cadherin family; it is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation."},"drugInfoSummaryLink":null,"nciConceptId":"C122405","nciConceptName":"Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101","termId":772801,"name":"yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-anti-cdh3-monoclonal-antibody-ff-21101"},{"aliases":[{"type":"LexicalVariant","name":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody cT84.66"}],"definition":{"html":"A radioimmunoconjugate comprised of a chimeric monoclonal antibody against human carcinoembryonic antigen (CEA) conjugated with  the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y90 DOTA anti-CEA monoclonal antibody cT84.66 binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","text":"A radioimmunoconjugate comprised of a chimeric monoclonal antibody against human carcinoembryonic antigen (CEA) conjugated with  the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y90 DOTA anti-CEA monoclonal antibody cT84.66 binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers."},"drugInfoSummaryLink":null,"nciConceptId":"C77885","nciConceptName":"Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66","termId":592860,"name":"yttrium Y 90 anti-CEA monoclonal antibody cT84.66","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-anti-cea-monoclonal-antibody-ct8466"},{"aliases":[{"type":"Synonym","name":"yttrium-90 carbon microspheres"}],"definition":{"html":"An injectable formulation composed of carbon microspheres loaded with the radioisotope yttrium Y 90, with potential antineoplastic activity. Upon administration, the yttrium Y 90 carbon microspheres selectively deliver a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression.","text":"An injectable formulation composed of carbon microspheres loaded with the radioisotope yttrium Y 90, with potential antineoplastic activity. Upon administration, the yttrium Y 90 carbon microspheres selectively deliver a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression."},"drugInfoSummaryLink":null,"nciConceptId":"C199634","nciConceptName":"Yttrium Y 90 Carbon Microspheres","termId":812505,"name":"yttrium Y 90 carbon microspheres","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-carbon-microspheres"},{"aliases":[{"type":"Synonym","name":"Y90 carbon microspheres NRT6003"},{"type":"Synonym","name":"yttrium-90 carbon microspheres NRT6003"},{"type":"CodeName","name":"NRT6003"},{"type":"CodeName","name":"NRT 6003"},{"type":"CodeName","name":"NRT-6003"}],"definition":{"html":"An injectable formulation composed of carbon microspheres loaded with the radioisotope yttrium Y 90, with potential antineoplastic activity. Upon administration, the yttrium Y 90 carbon microspheres NRT6003 selectively deliver a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression.\n","text":"An injectable formulation composed of carbon microspheres loaded with the radioisotope yttrium Y 90, with potential antineoplastic activity. Upon administration, the yttrium Y 90 carbon microspheres NRT6003 selectively deliver a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C212041","nciConceptName":"Yttrium Y 90 Carbon Microspheres NRT6003","termId":816975,"name":"yttrium Y 90 carbon microspheres NRT6003","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-carbon-microspheres-nrt6003"},{"aliases":[{"type":"Abbreviation","name":"Y90 DOTA MOAB HuPAM4"},{"type":"Synonym","name":"yttrium Y 90 DOTA monoclonal antibody HuPAM4"},{"type":"CodeName","name":"IMMU-107"},{"type":"Synonym","name":"90Y-hPAM4"},{"type":"Synonym","name":"hPAM4-DOTA"}],"definition":{"html":"A radioimmunoconjugate comprised of the humanized monoclonal antibody HuPAM4, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, selectively delivering a cytotoxic dose of beta radiation.","text":"A radioimmunoconjugate comprised of the humanized monoclonal antibody HuPAM4, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, selectively delivering a cytotoxic dose of beta radiation."},"drugInfoSummaryLink":null,"nciConceptId":"C48429","nciConceptName":"Yttrium Y-90 Clivatuzumab Tetraxetan","termId":425350,"name":"yttrium Y 90 clivatuzumab tetraxetan","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-clivatuzumab-tetraxetan"},{"aliases":[{"type":"Synonym","name":"90Y colloid"}],"definition":{"html":"An injectable, colloidal formulation of the radioisotope yttrium Y 90, with potential antineoplastic activity. When injected into the tumor, the yttrium Y 90 colloid selectively delivers a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression.","text":"An injectable, colloidal formulation of the radioisotope yttrium Y 90, with potential antineoplastic activity. When injected into the tumor, the yttrium Y 90 colloid selectively delivers a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression."},"drugInfoSummaryLink":null,"nciConceptId":"C114495","nciConceptName":"Yttrium Y 90 Colloid","termId":759092,"name":"yttrium Y 90 colloid","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-colloid"},{"aliases":[{"type":"Synonym","name":"Y90 MOAB anti-Tac"},{"type":"Synonym","name":"Y90 daclizumab"}],"definition":{"html":"A synthetic radioimmunoconjugate comprised of a humanized anti-interleukin-2 (IL-2) antibody linked to the radioisotope Yttrium 90 with potential antineoplastic activity.  Daclizumab binds with high affinity to the Tac (also called CD25) subunit of the IL-2 receptor complex and inhibits the binding of IL-2, thereby blocking the IL-2-mediated activation of lymphocytes.  As Yttrium Y 90 daclizumab, daclizumab delivers radiation specifically to lymphocytes that express the IL-2 receptor.","text":"A synthetic radioimmunoconjugate comprised of a humanized anti-interleukin-2 (IL-2) antibody linked to the radioisotope Yttrium 90 with potential antineoplastic activity.  Daclizumab binds with high affinity to the Tac (also called CD25) subunit of the IL-2 receptor complex and inhibits the binding of IL-2, thereby blocking the IL-2-mediated activation of lymphocytes.  As Yttrium Y 90 daclizumab, daclizumab delivers radiation specifically to lymphocytes that express the IL-2 receptor."},"drugInfoSummaryLink":null,"nciConceptId":"C2600","nciConceptName":"Yttrium Y 90 Daclizumab","termId":38097,"name":"yttrium Y 90 daclizumab","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-daclizumab"},{"aliases":null,"definition":{"html":"A radioimmunoconjugate consisting of a monoclonal antibody directed against the human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA)  with potential antineoplastic activity. The antibody moiety of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.","text":"A radioimmunoconjugate consisting of a monoclonal antibody directed against the human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA)  with potential antineoplastic activity. The antibody moiety of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers."},"drugInfoSummaryLink":null,"nciConceptId":"C77853","nciConceptName":"Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A","termId":592693,"name":"yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-dota-anti-cea-monoclonal-antibody-m5a"},{"aliases":[{"type":"Abbreviation","name":"90Y-DOTA-biotin"}],"definition":{"html":"A radioconjugate of biotin and yttrium Y 90 (Y-90) linked through the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) with radioimmunotherapy property. Biotin is a water-soluble B-complex vitamin, present in minute amounts in every living cell, while its level in cancerous tissue is higher than that of normal tissue. Y 90-DOTA-biotin could be used in 3-step pre-targeting radioimmunotherapy that employs a tumor targeting antibody conjugated with streptavidin, the natural ligand of biotin.","text":"A radioconjugate of biotin and yttrium Y 90 (Y-90) linked through the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) with radioimmunotherapy property. Biotin is a water-soluble B-complex vitamin, present in minute amounts in every living cell, while its level in cancerous tissue is higher than that of normal tissue. Y 90-DOTA-biotin could be used in 3-step pre-targeting radioimmunotherapy that employs a tumor targeting antibody conjugated with streptavidin, the natural ligand of biotin."},"drugInfoSummaryLink":null,"nciConceptId":"C1808","nciConceptName":"Yttrium Y 90-DOTA-Biotin","termId":365680,"name":"yttrium Y 90 DOTA-biotin","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-dota-biotin"},{"aliases":[{"type":"Synonym","name":"Y 90 Humanized Monoclonal Antibody LL2"},{"type":"Synonym","name":"Yttrium Y 90 Humanized Monoclonal Antibody LL2"}],"definition":{"html":"A radioimmunoconjugate consisting of  the anti-CD22 monoclonal antibody epratuzumab chelated to the radioisotope yttrium-90 (Y 90).  Yttrium Y 90 epratuzumab binds to tumor cells expressing CD22, delivering a cytotoxic dose of beta radiation. Epratuzumab is a humanized version of the murine monoclonal antibody LL2; CD22 is a B cell-restricted antigen present on the surfaces of mature B cells.","text":"A radioimmunoconjugate consisting of  the anti-CD22 monoclonal antibody epratuzumab chelated to the radioisotope yttrium-90 (Y 90).  Yttrium Y 90 epratuzumab binds to tumor cells expressing CD22, delivering a cytotoxic dose of beta radiation. Epratuzumab is a humanized version of the murine monoclonal antibody LL2; CD22 is a B cell-restricted antigen present on the surfaces of mature B cells."},"drugInfoSummaryLink":null,"nciConceptId":"C2582","nciConceptName":"Yttrium Y-90 Epratuzumab Tetraxetan","termId":43648,"name":"yttrium Y 90 epratuzumab","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-epratuzumab-tetraxetan"},{"aliases":[{"type":"USBrandName","name":"TheraSphere"}],"definition":{"html":"An injectable formulation of yttrium Y 90 consisting of glass microspheres containing the radioisotope yttrium Y 90.  When injected into the tumor vascular bed, yttrium Y 90 glass microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, thereby reducing the tumor burden.","text":"An injectable formulation of yttrium Y 90 consisting of glass microspheres containing the radioisotope yttrium Y 90.  When injected into the tumor vascular bed, yttrium Y 90 glass microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, thereby reducing the tumor burden."},"drugInfoSummaryLink":null,"nciConceptId":"C38679","nciConceptName":"Yttrium Y 90 Glass Microspheres","termId":38672,"name":"yttrium Y 90 glass microspheres","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-glass-microspheres"},{"aliases":[{"type":"CodeName","name":"IDEC Y2B8"},{"type":"LexicalVariant","name":"IDEC Y2B8"},{"type":"Synonym","name":"Y90 Zevalin"},{"type":"Synonym","name":"90Y ibritumomab tiuxetan"},{"type":"Synonym","name":"IDEC-Y2B8 monoclonal antibody"},{"type":"LexicalVariant","name":"IDEC-Y2B8 monoclonal antibody"},{"type":"NSCNumber","name":"710085"}],"definition":{"html":"A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90).  Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.","text":"A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90).  Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation."},"drugInfoSummaryLink":null,"nciConceptId":"C1812","nciConceptName":"Yttrium Y-90 Ibritumomab Tiuxetan","termId":38483,"name":"yttrium Y 90 ibritumomab tiuxetan","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-ibritumomab-tiuxetan"},{"aliases":[{"type":"Synonym","name":"MOAB B3, yttrium Y 90"},{"type":"Synonym","name":"Y 90 monoclonal antibody B3"},{"type":"Synonym","name":"90 Y-B3"},{"type":"Abbreviation","name":"Y90-B3"}],"definition":{"html":"A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses.","text":"A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses."},"drugInfoSummaryLink":null,"nciConceptId":"C2614","nciConceptName":"Yttrium Y 90 Monoclonal Antibody B3","termId":38188,"name":"yttrium Y 90 monoclonal antibody B3","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-monoclonal-antibody-b3"},{"aliases":[{"type":"Synonym","name":"MOAB BrE-3, yttrium Y 90"}],"definition":{"html":"A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90. Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation.","text":"A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90. Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation."},"drugInfoSummaryLink":null,"nciConceptId":"C2607","nciConceptName":"Yttrium Y 90 Monoclonal Antibody BrE-3","termId":38148,"name":"yttrium Y 90 monoclonal antibody BrE-3","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-monoclonal-antibody-bre-3"},{"aliases":[{"type":"Synonym","name":"Y90 MOAB Hu3S193"}],"definition":{"html":"A radioimmunotherapeutic agent consisting of a humanized murine monoclonal antibody (hu3S193) directed against the tumor-associated Lewis Y epithelial antigen chelated to the radioisotope yttrium-90.  Yttrium Y 90 monoclonal antibody Hu3S193 binds to Lewis Y epithelial antigen-expressing tumor cells, selectively delivering a cytotoxic dose of beta radiation.","text":"A radioimmunotherapeutic agent consisting of a humanized murine monoclonal antibody (hu3S193) directed against the tumor-associated Lewis Y epithelial antigen chelated to the radioisotope yttrium-90.  Yttrium Y 90 monoclonal antibody Hu3S193 binds to Lewis Y epithelial antigen-expressing tumor cells, selectively delivering a cytotoxic dose of beta radiation."},"drugInfoSummaryLink":null,"nciConceptId":"C38678","nciConceptName":"Yttrium Y 90 Monoclonal Antibody Hu3S193","termId":340956,"name":"yttrium Y 90 monoclonal antibody Hu3S193","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-monoclonal-antibody-hu3s193"},{"aliases":[{"type":"LexicalVariant","name":"MOAB MN-14, yttrium Y 90"},{"type":"LexicalVariant","name":"Y90 MOAB MN-14"},{"type":"LexicalVariant","name":"Y90 monoclonal antibody MN-14"},{"type":"LexicalVariant","name":"monoclonal antibody MN-14, yttrium Y 90"},{"type":"Synonym","name":"yttrium Y 90 MOAB MN-14"},{"type":"Synonym","name":"Y 90 Monoclonal Antibody MN-14"},{"type":"Abbreviation","name":"Y 90 MoAb MN-14"}],"definition":{"html":"A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Y 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation.","text":"A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Y 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation."},"drugInfoSummaryLink":null,"nciConceptId":"C2249","nciConceptName":"Yttrium Y 90 Monoclonal Antibody MN-14","termId":43511,"name":"yttrium Y 90 monoclonal antibody MN-14","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-monoclonal-antibody-mn-14"},{"aliases":null,"definition":{"html":"An injectable formulation of the radioisotope yttrium Y 90 encapsulated in resin microspheres with potential antineoplastic activity. When injected into  arterial vasculature supplying the tumor, yttrium Y 90 resin microspheres occlude tumor blood vessels and selectively deliver a cytotoxic dose of beta emitting yttrium Y 90 to the tumor site, which may result in tumor cell death and tumor regression.","text":"An injectable formulation of the radioisotope yttrium Y 90 encapsulated in resin microspheres with potential antineoplastic activity. When injected into  arterial vasculature supplying the tumor, yttrium Y 90 resin microspheres occlude tumor blood vessels and selectively deliver a cytotoxic dose of beta emitting yttrium Y 90 to the tumor site, which may result in tumor cell death and tumor regression."},"drugInfoSummaryLink":null,"nciConceptId":"C64539","nciConceptName":"Yttrium Y 90 Resin Microspheres","termId":523414,"name":"yttrium Y 90 resin microspheres","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-resin-microspheres"},{"aliases":[{"type":"Synonym","name":"90Y tabituximab barzuxetan"},{"type":"Synonym","name":"yttrium Y 90-labeled anti-FZD10 monoclonal antibody OTSA101"},{"type":"Abbreviation","name":"OTSA101-DTPA-90Y"}],"definition":{"html":"A radioimmunoconjugate composed of a humanized monoclonal antibody (MoAb) tabituximab barzuxetan against FZD10 and labeled with yttrium Y 90, with potential antineoplastic activity. The MoAb moiety of yttrium Y 90 tabituximab barzuxetan binds to FZD10, thereby delivering a cytotoxic dose of beta radiation to FZD10 positive tumor cells. FZD10 (also called CD350), a member of the Frizzled family of G protein-coupled receptors that is involved in the Wnt/beta-catenin/TCF signaling pathway, is overexpressed in a variety of cancer cell types but undetectable in normal, healthy human tissues except the placenta.","text":"A radioimmunoconjugate composed of a humanized monoclonal antibody (MoAb) tabituximab barzuxetan against FZD10 and labeled with yttrium Y 90, with potential antineoplastic activity. The MoAb moiety of yttrium Y 90 tabituximab barzuxetan binds to FZD10, thereby delivering a cytotoxic dose of beta radiation to FZD10 positive tumor cells. FZD10 (also called CD350), a member of the Frizzled family of G protein-coupled receptors that is involved in the Wnt/beta-catenin/TCF signaling pathway, is overexpressed in a variety of cancer cell types but undetectable in normal, healthy human tissues except the placenta."},"drugInfoSummaryLink":null,"nciConceptId":"C99168","nciConceptName":"Yttrium Y 90 Tabituximab Barzuxetan","termId":717536,"name":"yttrium Y 90 tabituximab barzuxetan","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-tabituximab-barzuxetan"},{"aliases":[{"type":"Abbreviation","name":"Y90 DOTA MOAB HuAFP31"},{"type":"LexicalVariant","name":"yttrium Y 90 DOTA monoclonal antibody HuAFP31"}],"definition":{"html":"A radioimmunoconjugate comprised of the monoclonal antibody HuAFP31, directed against alpha fetoprotein, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 tacatuzumab tetraxetan binds to tumor cells expressing alpha fetoprotein, selectively delivering a cytotoxic dose of beta radiation. ","text":"A radioimmunoconjugate comprised of the monoclonal antibody HuAFP31, directed against alpha fetoprotein, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 tacatuzumab tetraxetan binds to tumor cells expressing alpha fetoprotein, selectively delivering a cytotoxic dose of beta radiation. "},"drugInfoSummaryLink":null,"nciConceptId":"C48428","nciConceptName":"Yttrium Y-90 Tacatuzumab Tetraxetan","termId":425347,"name":"yttrium Y 90 tacatuzumab tetraxetan","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-tacatuzumab-tetraxetan"},{"aliases":[{"type":"Abbreviation","name":"90-Y-IMP-288"},{"type":"Abbreviation","name":"90Y-IMP288"}],"definition":{"html":"A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the beta-emitting radionuclide yttrium 90 (Y-90), with radioimmunotherapeutic activity. After pre-treating and targeting tumor cells with a bi-specific monoclonal antibody (BiMoAB) directed against both a tumor-associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of the administered yttrium Y 90-DOTA-di-HSG peptide IMP-288 binds to the anti-HSG sequence on the BiMoAB. In turn, Y-90 delivers a cytotoxic dose of beta radiation to tumor cells expressing the specific TAA.","text":"A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the beta-emitting radionuclide yttrium 90 (Y-90), with radioimmunotherapeutic activity. After pre-treating and targeting tumor cells with a bi-specific monoclonal antibody (BiMoAB) directed against both a tumor-associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of the administered yttrium Y 90-DOTA-di-HSG peptide IMP-288 binds to the anti-HSG sequence on the BiMoAB. In turn, Y-90 delivers a cytotoxic dose of beta radiation to tumor cells expressing the specific TAA."},"drugInfoSummaryLink":null,"nciConceptId":"C119738","nciConceptName":"Yttrium Y 90-DOTA-di-HSG Peptide IMP-288","termId":766993,"name":"yttrium Y 90-DOTA-di-HSG peptide IMP-288","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-dota-di-hsg-peptide-imp-288"},{"aliases":[{"type":"Abbreviation","name":"90Y-DOTA-cG250"},{"type":"Synonym","name":"yttrium Y 90 DOTA chimeric monoclonal antibody cG250"}],"definition":{"html":"A radioimmunoconjugate comprised of girentuximab conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and lableled with  the beta-emitting radioisotope yttrium Y 90. The antibody moiety of yttrium Y 90-DOTA-girentuximab binds to renal cell carcinoma cells expressing the G250 antigen,  thereby selectively delivering a cytotoxic dose of beta radiation.  ","text":"A radioimmunoconjugate comprised of girentuximab conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and lableled with  the beta-emitting radioisotope yttrium Y 90. The antibody moiety of yttrium Y 90-DOTA-girentuximab binds to renal cell carcinoma cells expressing the G250 antigen,  thereby selectively delivering a cytotoxic dose of beta radiation.  "},"drugInfoSummaryLink":null,"nciConceptId":"C53409","nciConceptName":"Yttrium Y-90-DOTA-Girentuximab","termId":465788,"name":"yttrium Y 90-DOTA-girentuximab","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-dota-girentuximab"},{"aliases":[{"type":"USBrandName","name":"Y-90 OctreoTher"},{"type":"Synonym","name":"yttrium Y 90 -DOTATOC"},{"type":"Synonym","name":"Y90-DOTA-tyr3-octreotide"},{"type":"Synonym","name":"yttrium Y 90 SMT 487"},{"type":"LexicalVariant","name":"yttrium Y 90-DOTA-tyr3-octreotide"},{"type":"CASRegistryName","name":"322407-70-5"},{"type":"Synonym","name":"90Y-DOTA-3-Tyr-octreotide"},{"type":"USBrandName","name":"OctreoTher"},{"type":"USBrandName","name":"Onalta"},{"type":"Synonym","name":"yttrium Y 90-DOTA-3-tyrosine-octreotide"}],"definition":{"html":"A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y 90-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells, delivering tissue-specific, beta-emitting nuclide Y-90-mediated cytotoxicity to SSTR-positive cells. Yttrium Y 90-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Y-90 via dodecanetetraacetic acid (DOTA).","text":"A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y 90-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells, delivering tissue-specific, beta-emitting nuclide Y-90-mediated cytotoxicity to SSTR-positive cells. Yttrium Y 90-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Y-90 via dodecanetetraacetic acid (DOTA)."},"drugInfoSummaryLink":null,"nciConceptId":"C2601","nciConceptName":"Yttrium Y 90-Edotreotide","termId":38102,"name":"yttrium Y 90-edotreotide","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-edotreotide"},{"aliases":[{"type":"Synonym","name":"90Y basiliximab"}],"definition":{"html":"A radioimmunoconjugate composed of basiliximab, a chimeric, mouse-human monoclonal antibody directed against the alpha subunit of interleukin-2 receptor (IL-2R alpha, CD25 or Tac antigen), and labeled with yttrium y 90, with potential antineoplastic activity. The basiliximab moiety of yttrium Y 90 basiliximab selectively binds to IL-2R alpha expressed on the surface of activated T-lymphocytes, thereby preventing IL-2 binding and blocking the IL-2-mediated activation of lymphocytes. The yttrium y 90 moiety selectively delivers a cytotoxic dose of beta radiation to lymphocytes that express the IL-2 receptor. This may prevent T cell-mediated activation of the immune system against a certain transplant and may prevent transplant rejection.","text":"A radioimmunoconjugate composed of basiliximab, a chimeric, mouse-human monoclonal antibody directed against the alpha subunit of interleukin-2 receptor (IL-2R alpha, CD25 or Tac antigen), and labeled with yttrium y 90, with potential antineoplastic activity. The basiliximab moiety of yttrium Y 90 basiliximab selectively binds to IL-2R alpha expressed on the surface of activated T-lymphocytes, thereby preventing IL-2 binding and blocking the IL-2-mediated activation of lymphocytes. The yttrium y 90 moiety selectively delivers a cytotoxic dose of beta radiation to lymphocytes that express the IL-2 receptor. This may prevent T cell-mediated activation of the immune system against a certain transplant and may prevent transplant rejection."},"drugInfoSummaryLink":null,"nciConceptId":"C99167","nciConceptName":"Yttrium Y 90 Basiliximab","termId":717514,"name":"yttrium Y 90-labeled basiliximab","firstLetter":"y","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"yttrium-y-90-basiliximab"}],"links":null}